Baseline demographics
| Total patients | 101 |
| Median age at diagnosis, y (range) | 57 (19-88) |
| Gender, female, n (%) | 39 (38.6%) |
| Race, n (%) | |
| White | 79 (78.2%) |
| East or South-Central Asian | 12 (11.9%) |
| Other | 10 (9.9%) |
| ELTS risk, n (%) | |
| Low | 73 (72.3%) |
| Intermediate | 22 (21.8%) |
| High | 5 (5.0%) |
| NA | 1 (1.0%) |
| Therapies before asciminib commencement, n (%) | |
| Prior hydroxyurea | 50 (49.5%) |
| Prior leukapheresis | 2 (2.0%) |
| Total patients | 101 |
| Median age at diagnosis, y (range) | 57 (19-88) |
| Gender, female, n (%) | 39 (38.6%) |
| Race, n (%) | |
| White | 79 (78.2%) |
| East or South-Central Asian | 12 (11.9%) |
| Other | 10 (9.9%) |
| ELTS risk, n (%) | |
| Low | 73 (72.3%) |
| Intermediate | 22 (21.8%) |
| High | 5 (5.0%) |
| NA | 1 (1.0%) |
| Therapies before asciminib commencement, n (%) | |
| Prior hydroxyurea | 50 (49.5%) |
| Prior leukapheresis | 2 (2.0%) |
ELTS, EUTOS long-term survival score; NA, not available.